Oncoinvent Calls Extraordinary General Meeting to Reshape Capital Structure

BerGenBio ASA ( (BRRGF) ) has shared an update.

Oncoinvent ASA, a clinical-stage biotech focused on radiopharmaceutical cancer therapies and developer of the radium-224-based candidate Radspherin for peritoneal carcinomatosis, continues to advance its pipeline through a global Phase 2 program supported by in-house manufacturing capabilities in Oslo. The company has called an extraordinary general meeting for 8 January 2026, to be held electronically, where shareholders will vote on an audited interim balance sheet, a reverse share split, a capital reduction and new board authorizations, measures that indicate an active effort to adjust the company’s capital structure and governance framework as it progresses its clinical and commercial ambitions.

The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.

More about BerGenBio ASA

Oncoinvent ASA is a clinical-stage biotechnology company specializing in novel radiopharmaceutical therapies for cancer. Its lead product candidate, Radspherin, is an investigational alpha-emitting radiopharmaceutical based on radium-224-loaded calcium carbonate microparticles, designed for local treatment of cancers that have spread to body cavities, particularly peritoneal carcinomatosis from ovarian and colorectal cancer. The company has completed early-phase clinical trials and is running a randomized Phase 2 trial in the US, UK and Europe, with encouraging efficacy signals and no serious safety concerns reported so far. Oncoinvent operates a state-of-the-art manufacturing facility in Oslo and is listed on the Oslo Stock Exchange.

Average Trading Volume: 853,265

Current Market Cap: NOK222.6M

Learn more about BRRGF stock on TipRanks’ Stock Analysis page.